Despite a disappointing advisory committee review for its progesterone gel for preterm birth, Watson said it will continue to push for approval. The company also bolsters its Australian generics business with the acquisition of Ascent.

[Editor's note: This is part two of a story carrying highlights on emerging markets from the annual JP Morgan Healthcare Conference in San Francisco last week.

The Sao Paolo-based company will market about a dozen of Watson's generics in Mexico and Brazil, with potential for more.